Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2311 to 2325 of 9102 results

  1. Cagrilintide–semaglutide for managing overweight and obesity

    Awaiting development Reference number: GID-TA12443 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Ivonescimab for untreated metastatic non-small-cell lung cancer with high PD-L1 expression

    Awaiting development Reference number: GID-TA12444 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

    In development Reference number: GID-HTG10902 Expected publication date: TBC

    HealthTech guidance
    In development

  4. Hearing aids for adults with hearing loss

    In development Reference number: GID-HTG10886 Expected publication date:  04 February 2027

    HealthTech guidance
    In development

  5. Domestic Abuse

    In development Reference number: GID-NG10449 Expected publication date:  23 February 2027

    NICE guideline
    In development

  6. Dabrafenib with trametinib for treating BRAF V600E mutation-positive advanced differentiated thyroid cancer after radioactive iodine and 1 or 2 VEGFR-targeted treatments

    Awaiting development Reference number: GID-TA12461 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests

    In development Reference number: GID-HTG10898 Expected publication date: TBC

    HealthTech guidance
    In development

  8. Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]

    Awaiting development Reference number: GID-TA11930 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Insulin efsitora alfa for treating type 2 diabetes [ID6499]

    In development Reference number: GID-TA11644 Expected publication date:  22 October 2026

    Technology appraisal guidance
    In development

  10. Severe mental illness guidance review

    In development Reference number: GID-NG10465 Expected publication date: TBC

    NICE guideline
    In development

  11. Familial Breast Cancer: initial assessment and genetic testing (update)

    In development Reference number: GID-NG10438 Expected publication date:  22 April 2027

    NICE guideline
    In development

  12. Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493]

    Awaiting development Reference number: GID-TA11639 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 1 July 2026.

    Technology appraisal guidance
    In consultation

  14. Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713

    In development Reference number: GID-TA11952 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Excimer laser trabeculotomy for open angle glaucoma

    Awaiting development Reference number: GID-HTG10469 Expected publication date: TBC

    HealthTech guidance
    Awaiting development